news

  • 8 November 2010
    Kuros regains rights to selected wound care and trauma clinical candidates from Baxter International Inc.

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has regained rights to a number of selected wound care and trauma clinical candidates that were previously licensed to Baxter International Inc.

    Kuros has regained rights to the following clinical candidates:

    • KUR-212 – which has completed a successful Phase IIa clinical trial in burns patients who require autologous mesh grafting

    • KUR-213 - which is being developed for an undisclosed acute wound indication and

    • KUR-112 – which is in clinical development for solitary bone cysts, an orphan indication

    Didier Cowling, Chief Executive Officer of Kuros, commenting on today’s announcement said: “I am glad that we have reached agreement with Baxter to regain the rights to these programs. The results that we have reported with products based on our proprietary TG-hook technology gives us confidence that these product candidates will be shown to deliver important benefits to patients. We are also looking forward to continuing to collaborate with Baxter on the Kuros programs to which they retain clinical development and commercialization rights.”

    Baxter continues to be the licensee for a number of other products for trauma indications based on Kuros “TG-hook” technology. These are KUR-111 which has delivered positive Phase IIb results in patients with tibial plateau fractures and KUR- 113, which is in a Phase IIb clinical trial in patients with open tibial shaft fractures. Baxter and Kuros are also partners in the development of KUR-211, a product for the treatment of chronic wounds which is currently in a large pan European Phase II study involving diabetic foot ulcer patients.

    Kuros and Baxter International Inc. signed their original collaboration and license agreement in 2005.

    About Kuros

    www.kuros.ch

    - Ends –

    Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications.Kuros’ combination products are designed to mimic the body’s natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.

    Kuros’ has a diverse pipeline of product candidates with its most advanced products being in trauma and wound care.

    Since its creation in 2000, Kuros has raised over $100 million. The company is located in Zurich, Switzerland.